SAGE Therapeutics Q3 Loss Widens

(RTTNews) - SAGE Therapeutics, Inc. (SAGE) posted third-quarter net loss attributable to common stockholders of $9.9 million, wider than $4.5 million. But, loss per share narrowed to $0.50 from $2.98 in the comparable quarter last year.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.40 per share.

Loss from operations widened to $9.5 million from $4.5 million in the year-ago period.

General and administrative expenses were $2.9 million in the third quarter of 2014, compared to $1.1 million for the third quarter of 2013. The increase in G&A expenses was largely due to personnel-related costs to support the activities associated with becoming a public company.